Compare YORW & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | YORW | CTNM |
|---|---|---|
| Founded | 1816 | 2009 |
| Country | United States | United States |
| Employees | 104 | N/A |
| Industry | Water Supply | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.4M | 480.5M |
| IPO Year | 1994 | 2024 |
| Metric | YORW | CTNM |
|---|---|---|
| Price | $29.53 | $14.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $34.00 | $19.00 |
| AVG Volume (30 Days) | 163.9K | ★ 264.8K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $77,488,000.00 | N/A |
| Revenue This Year | $11.78 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | $88.39 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $28.26 | $3.35 |
| 52 Week High | $34.30 | $16.33 |
| Indicator | YORW | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 60.97 |
| Support Level | $28.26 | $13.86 |
| Resistance Level | $32.13 | $14.63 |
| Average True Range (ATR) | 0.61 | 0.91 |
| MACD | 0.01 | 0.24 |
| Stochastic Oscillator | 57.03 | 71.17 |
The York Water Co is the investor-owned water utility in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. The company also owns and operates three wastewater collection systems and twelve wastewater collection and treatment systems. The company operates within its franchised water and wastewater territory, which covers portions of municipalities within four counties in south-central Pennsylvania. It provides services to diversified, manufacturing such items as fixtures and furniture, electrical machinery, food products, paper, ordnance units, textile products, air conditioning systems, laundry detergent, barbells, and motorcycles.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.